Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A
- 1 January 2000
- journal article
- clinical trial
- Published by Elsevier in Kidney International
- Vol. 57 (1) , 224-231
- https://doi.org/10.1046/j.1523-1755.2000.00838.x
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Endothelins in the normal and diseased kidneyAmerican Journal of Kidney Diseases, 1997
- Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjectsClinical Pharmacology & Therapeutics, 1996
- Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in malesJournal Of Hypertension, 1995
- Effects of endothelin-1 on renal function in humans: Implications for physiology and PathophysiologyKidney International, 1994
- Renal actions of endothelin: Linking cellular signaling pathways to kidney diseaseKidney International, 1994
- Cyclosporine A induces endothelin-1 release from cultured rat vascular smooth muscle cellsEuropean Journal of Pharmacology, 1993
- Endothelin receptor antagonism is protective in in vivo acute cyclosporine toxicityKidney International, 1992
- DAILY RENAL HYPOPERFUSION INDUCED BY CYCLOSPORINE IN PATIENTS WITH RENAL TRANSPLANTATIONTransplantation, 1992
- Cyclosporine-induced synthesis of endothelin by cultured human endothelial cells.Journal of Clinical Investigation, 1991
- Role of endothelin in cyclosporine-induced glomerular dysfunctionKidney International, 1990